Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer von Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, Krop, Ian

Volltext

Advances in Targeted Therapies for Triple-Negative Breast Cancer von McCann, Kelly E., Hurvitz, Sara A., McAndrew, Nicholas

Volltext

Multimorbidity in Middle-Aged Adults with Cerebral Palsy von Cremer, Nicole, B.S, Hurvitz, Edward A., M.D, Peterson, Mark D., Ph.D., M.S

Volltext

Advances in the use of PARP inhibitor therapy for breast cancer von McCann, Kelly E, Hurvitz, Sara A

Volltext

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study von Hurvitz, Sara A, Martin, Miguel, Jung, Kyung Hae, Huang, Chiun-Sheng, Harbeck, Nadia, Valero, Vicente, Stroyakovskiy, Daniil, Wildiers, Hans, Campone, Mario, Boileau, Jean-François, Fasching, Peter A, Afenjar, Karen, Spera, Gonzalo, Lopez-Valverde, Vanesa, Song, Chunyan, Trask, Peter, Boulet, Thomas, Sparano, Joseph A, Symmans, W Fraser, Thompson, Alastair M, Slamon, Dennis

Volltext

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer von HURVITZ, Sara A, DIRIX, Luc, CHU, Yu-Waye, PEREZ, Edith A, KOCSIS, Judit, BIANCHI, Giulia V, LU, Janice, VINHOLES, Jeferson, GUARDINO, Ellie, CHUNYAN SONG, TONG, Barbara, NG, Vivian

Volltext

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer von O'Brien, Neil A., McDermott, Martina S. J., Conklin, Dylan, Luo, Tong, Ayala, Raul, Salgar, Suruchi, Chau, Kevin, DiTomaso, Emmanuelle, Babbar, Naveen, Su, Faye, Gaither, Alex, Hurvitz, Sara A., Linnartz, Ronald, Rose, Kristine, Hirawat, Samit, Slamon, Dennis J.

Volltext

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer von Rugo, Hope S, Klein, Paula, Melin, Susan Anitra, Hurvitz, Sara A, Melisko, Michelle E, Moore, Anne, Park, Glen, Mitchel, Jules, Bågeman, Erika, D’Agostino, Ralph B, Ver Hoeve, Elizabeth S, Esserman, Laura, Cigler, Tessa

Volltext

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-... von Hurvitz, Sara A, Dr, Andre, Fabrice, Prof, Jiang, Zefei, Prof, Shao, Zhimin, Prof, Mano, Max S, MD, Neciosup, Silvia P, MD, Tseng, Ling-Min, MD, Zhang, Qingyuan, Prof, Shen, Kunwei, Prof, Liu, Donggeng, Prof, Dreosti, Lydia M, Prof, Burris, Howard A, MD, Toi, Masakazu, Prof, Buyse, Marc E, Prof, Cabaribere, David, MSc, Lindsay, Mary-Ann, PhD, Rao, Shantha, PhD, Pacaud, Lida Bubuteishvili, MD, Taran, Tetiana, MD, Slamon, Dennis, Prof

Volltext

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–pos... von Welslau, Manfred, Diéras, Veronique, Sohn, Joo‐Hyuk, Hurvitz, Sara A., Lalla, Deepa, Fang, Liang, Althaus, Betsy, Guardino, Ellie, Miles, David

Volltext

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III stu... von de Haas, Sanne L, Slamon, Dennis J, Martin, Miguel, Press, Michael F, Lewis, Gail D, Lambertini, Chiara, Prat, Aleix, Lopez-Valverde, Vanesa, Boulet, Thomas, Hurvitz, Sara A

Volltext

Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy von Zoeller, Jason J, Press, Michael F, Selfors, Laura M, Dering, Judy, Slamon, Dennis J, Hurvitz, Sara A, Brugge, Joan S

Volltext

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT von O'Brien, Neil A, McDonald, Karen, Tong, Luo, von Euw, Erika, Kalous, Ondrej, Conklin, Dylan, Hurvitz, Sara A, di Tomaso, Emmanuelle, Schnell, Christian, Linnartz, Ronald, Finn, Richard S, Hirawat, Samit, Slamon, Dennis J

Volltext

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab von ANDRE, Fabrice, CAMPONE, Mario, O'REGAN, Ruth, MANLIUS, Corinne, MASSACESI, Cristian, SAHMOUD, Tarek, MUKHOPADHYAY, Pabak, SORIA, Jean-Charles, NAUGHTON, Michael, HURVITZ, Sara A

Volltext

DESTINY-Changing Results for Advanced Breast Cancer von Hurvitz, Sara A.

Volltext

Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma von ANSELL, Stephen M, HURVITZ, Sara A, ERLICHMAN, Charles, LOWY, Israel, TIMMERMAN, John M, KOENIG, Patricia A, LAPLANT, Betsy R, KABAT, Brian F, FERNANDO, Donna, HABERMANN, Thomas M, INWARDS, David J, VERMA, Meena, YAMADA, Reiko

Volltext

Antibody-drug conjugates: an emerging modality for the treatment of cancer von Leal, Mauricio, Sapra, Puja, Hurvitz, Sara A., Senter, Peter, Wahl, Alan, Schutten, Melissa, Shah, Dhaval K., Haddish-Berhane, Nahor, Kabbarah, Omar

Volltext

Clinical features of pseudocirrhosis in metastatic breast cancer von Oliai, Caspian, Douek, Michael L., Rhoane, Caelainn, Bhutada, Abhishek, Ge, Phillip S., Runyon, Bruce A., Wang, Xiaoyan, Hurvitz, Sara A.

Volltext

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential von Peddi, Parvin F., Hurvitz, Sara A.

Volltext

Shared Physiologic Pathways Among Comorbidities for Adults With Cerebral Palsy von Whitney, Daniel G., Schmidt, Mary, Hurvitz, Edward A.

Volltext